Developer docs
API playgroundTry for free, no card

Search company profiles

Midatech Pharma PLC

Full company profile

uuid02lsjrq

Namestring
Midatech Pharma PLC
Legal namestring
Biodexa Pharmaceuticals PLC
Company typeenum
Public
Founded yearstring
-
Descriptiontext

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), doing business as Biodexa and referred to in some source records as Midatech Pharma PLC, is a clinical-stage biopharmaceutical company headquartered in the United Kingdom and developing a pipeline of treatments for diseases with high unmet medical need. The company's portfolio is centered on three core programs: eRapa, MTX240, and Tolimidone. eRapa is a proprietary oral tablet formulation of rapamycin (sirolimus), an mTOR inhibitor, that uses nanotechnology and pH sensitive polymers to improve bioavailability and produce more consistent pharmacokinetics than existing formulations. It is being readied for a Phase 3 registration study — branded the Serenta Trial — in familial adenomatous polyposis (FAP), a rare condition for which the only current effective intervention is bowel resection and where patients otherwise progress to colorectal cancer. MTX240 is a next-generation molecular glue (OPB-171775) licensed exclusively from Otsuka for all territories outside Japan, targeting TKI-resistant gastrointestinal stromal tumor (GIST). Tolimidone is an orally delivered, selective inhibitor of lyn kinase that has demonstrated glycemic control via insulin sensitization in animal models of type 1 diabetes.

Biodexa's underlying technology platform combines proprietary drug formulation science (nanotechnology and pH-sensitive polymer engineering applied to a known active pharmaceutical ingredient), an in-licensed targeted protein degradation asset, and a small-molecule kinase inhibitor approach. Its competitive positioning rests on the established safety profile of rapamycin (approved in the US for renal transplant rejection), the territorial exclusivity of the Otsuka license, and the orphan/rare-disease nature of the lead indications, where existing therapeutic options are limited.

The business is pre-revenue and pre-commercial: the company generates no product sales, has not disclosed pricing, and does not yet employ traditional go-to-market or distribution channels. Its activity is concentrated on clinical development, regulatory progression, and capital-markets engagement via its NASDAQ listing, with a Serenta Trial patient-recruitment website and standard investor-relations infrastructure as its principal outward-facing assets.

Short descriptiontext

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company developing eRapa (oral rapamycin) for familial adenomatous polyposis, MTX240 (a molecular glue) for TKI-resistant GIST, and Tolimidone (a lyn kinase inhibitor) for type 1 diabetes, targeting rare and serious diseases with unmet medical need.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
Markets served

Serves global market

Keyword5 values
clinical-stage biopharmaceutical, rare disease therapeutics, oral rapamycin formulation, molecular glue degraders, mTOR inhibitor drugs
Industry2 codes
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Nanotechnology541713
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Rare Disease Biopharmaceuticals
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Biodexa Pharmaceuticals PLC (formerly Midatech Pharma PLC) is a clinical-stage biopharmaceutical company developing a pipeline of therapeutics for rare and serious diseases with high unmet medical need. Its lead asset eRapa is a proprietary oral tablet formulation of rapamycin using nanotechnology and pH-sensitive polymers, being readied for a Phase 3 study in familial adenomatous polyposis (FAP). The pipeline also includes MTX240, a next-generation molecular glue licensed from Otsuka for TKI-resistant GIST, and Tolimidone, an oral lyn kinase inhibitor with potential first-in-class application in type 1 diabetes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • eRapa is being readied for phase 3 registration study in familial adenomatous polyposis (FAP)
+2 more records
Product overview1 text field

Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company developing a pipeline of treatments aimed at diseases with high unmet clinical need. The company operates three core programs: eRapa (oral rapamycin formulation for FAP, in phase 3 readiness), MTX240 (molecular glue for TKI-resistant GIST), and Tolimidone (lyn kinase inhibitor for type 1 diabetes). The company is also working on treatments for primary and metastatic cancers of the brain.

Product and service4 records
1eRapa
CategoryCore Product — Rare Disease Oncology / FAP
Description

Proprietary oral tablet formulation of rapamycin (sirolimus), an mTOR inhibitor, designed to improve bioavailability and achieve more consistent pharmacokinetics than existing formulations. Lead indication is familial adenomatous polyposis (FAP), a rare condition where the only successful treatment is bowel resection and patients otherwise progress to colorectal cancer. Rapamycin is already approved in the US for organ rejection in renal transplantation.

2MTX240 (OPB-171775)
CategoryCore Product — Oncology / TKI-resistant GIST
Description

Next-generation molecular glue (OPB-171775) targeting TKI-resistant gastrointestinal stromal tumor (GIST), a rare sarcoma with approximately 4,000-6,000 new US cases annually. Induces selective protein degradation to overcome standard-of-care limitations such as imatinib resistance. Licensed exclusively from Otsuka in all territories outside Japan.

3Tolimidone
CategoryCore Product — Type 1 Diabetes / Metabolic Disease
Description

Orally delivered, potent and selective inhibitor of lyn kinase, a member of the Src family of protein tyrosine kinases mainly expressed in hematopoietic cells, neural tissues, liver, and adipose tissue. Demonstrates glycemic control via insulin sensitization in animal models of diabetes and has potential to become a first-in-class blood glucose modulating agent for type 1 diabetes.

4Serenta Trial
CategoryClinical Trial — Phase 3 Study in FAP
Description

Phase 3 clinical study evaluating eRapa versus placebo for the ability to improve clinical outcomes in patients with familial adenomatous polyposis (FAP). The study is open for enrollment in the US and is conducted through clinical trial sites.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharma with a Type 1 diabetes program, directly comparable to Biodexa's Tolimidone. Both pursue novel, non-insulin mechanisms for T1D glycemic control from a small-cap clinical base.

TypeDirect peer
Description

Pioneered approved GIST therapy (Qinlock/ripretinib) for TKI-resistant disease. Operates in the same rare oncology niche as Biodexa's MTX240 and shares the same clinical-stage-to-commercial rare disease playbook.

TypeBroad incumbent
Description

Larger clinical-to-commercial oncology company developing targeted therapies including protein degraders and RAS inhibitors. Operates in the same novel-mechanism oncology space as Biodexa but at a more advanced and broader scale.

TypeBroad incumbent
Description

Established precision oncology biopharma with approved kinase inhibitors and broader pipeline. Comparable in therapeutic area (targeted oncology) but at a more advanced commercial and scale stage than Biodexa.

TypeEmerging player
Description

Clinical-stage company developing molecular glue / targeted protein degradation therapies in oncology. Mechanism overlap with Biodexa's MTX240 makes it a comparable emerging player in the same modality class.

TypeDirect peer
Description

Clinical-stage biopharma developing treatments for endocrine and metabolic rare diseases. Comparable specialty-pharma positioning, therapeutic area overlap (endocrine/metabolic), and similar small-cap clinical-stage operating model.

TypeEmerging player
Description

Clinical-stage biopharma developing novel biologics including targeted protein degradation approaches. Comparable as a small-cap clinical-stage innovator pursuing novel therapeutic modalities in oncology and serious diseases.

TypeEmerging player
Description

Small-cap biopharma with diabetes and metabolism programs historically. Shares Biodexa's small-cap, clinical-stage profile and metabolic disease focus, though its development stage differs.

TypeDirect peer
Description

Clinical-stage biopharma developing treatments for TKI-resistant GIST, directly overlapping with Biodexa's MTX240 program. Same rare sarcoma indication and similar resistance-focused mechanism positioning make it the closest direct comparable.

TypeDirect peer
Description

Was focused on Type 1 diabetes therapies (teplizumab) before acquisition by Sanofi. Closely comparable to Biodexa in targeting T1D as a clinical-stage specialty biopharma.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Midatech Pharma PLC

Clinical-Stage Rare Disease Biopharmaceuticalsmidatechpharma.com

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company developing eRapa (oral rapamycin) for familial adenomatous polyposis, MTX240 (a molecular glue) for TKI-resistant GIST, and Tolimidone (a lyn kinase inhibitor) for type 1 diabetes, targeting rare and serious diseases with unmet medical need.

What Midatech Pharma PLC does

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), doing business as Biodexa and referred to in some source records as Midatech Pharma PLC, is a clinical-stage biopharmaceutical company headquartered in the United Kingdom and developing a pipeline of treatments for diseases with high unmet medical need. The company's portfolio is centered on three core programs: eRapa, MTX240, and Tolimidone. eRapa is a proprietary oral tablet formulation of rapamycin (sirolimus), an mTOR inhibitor, that uses nanotechnology and pH sensitive polymers to improve bioavailability and produce more consistent pharmacokinetics than existing formulations. It is being readied for a Phase 3 registration study — branded the Serenta Trial — in familial adenomatous polyposis (FAP), a rare condition for which the only current effective intervention is bowel resection and where patients otherwise progress to colorectal cancer. MTX240 is a next-generation molecular glue (OPB-171775) licensed exclusively from Otsuka for all territories outside Japan, targeting TKI-resistant gastrointestinal stromal tumor (GIST). Tolimidone is an orally delivered, selective inhibitor of lyn kinase that has demonstrated glycemic control via insulin sensitization in animal models of type 1 diabetes.

Biodexa's underlying technology platform combines proprietary drug formulation science (nanotechnology and pH-sensitive polymer engineering applied to a known active pharmaceutical ingredient), an in-licensed targeted protein degradation asset, and a small-molecule kinase inhibitor approach. Its competitive positioning rests on the established safety profile of rapamycin (approved in the US for renal transplant rejection), the territorial exclusivity of the Otsuka license, and the orphan/rare-disease nature of the lead indications, where existing therapeutic options are limited.

The business is pre-revenue and pre-commercial: the company generates no product sales, has not disclosed pricing, and does not yet employ traditional go-to-market or distribution channels. Its activity is concentrated on clinical development, regulatory progression, and capital-markets engagement via its NASDAQ listing, with a Serenta Trial patient-recruitment website and standard investor-relations infrastructure as its principal outward-facing assets.

Midatech Pharma PLC firmographics

Firmographics
Name
Midatech Pharma PLC
Legal name
Biodexa Pharmaceuticals PLC
Website
https://midatechpharma.com
Company type
Public
Operating status
Operating
Short description
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company developing eRapa (oral rapamycin) for familial adenomatous polyposis, MTX240 (a molecular glue) for TKI-resistant GIST, and Tolimidone (a lyn kinase inhibitor) for type 1 diabetes, targeting rare and serious diseases with unmet medical need.
Ownership category
akta.pro rank

Midatech Pharma PLC industry classification

Industry
Product category
Clinical-Stage Rare Disease Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Nanotechnology (541713), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceutical
  • Rare disease therapeutics
  • Oral rapamycin formulation
  • Molecular glue degraders
  • MTOR inhibitor drugs

Midatech Pharma PLC business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Distribution channels2 records

Marketing channels5 records

Midatech Pharma PLC product offering

Product offering

Core offering

Biodexa Pharmaceuticals PLC (formerly Midatech Pharma PLC) is a clinical-stage biopharmaceutical company developing a pipeline of therapeutics for rare and serious diseases with high unmet medical need. Its lead asset eRapa is a proprietary oral tablet formulation of rapamycin using nanotechnology and pH-sensitive polymers, being readied for a Phase 3 study in familial adenomatous polyposis (FAP). The pipeline also includes MTX240, a next-generation molecular glue licensed from Otsuka for TKI-resistant GIST, and Tolimidone, an oral lyn kinase inhibitor with potential first-in-class application in type 1 diabetes.

Product overview

Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company developing a pipeline of treatments aimed at diseases with high unmet clinical need. The company operates three core programs: eRapa (oral rapamycin formulation for FAP, in phase 3 readiness), MTX240 (molecular glue for TKI-resistant GIST), and Tolimidone (lyn kinase inhibitor for type 1 diabetes). The company is also working on treatments for primary and metastatic cancers of the brain.

Differentiator

Problem solved

Functional benefit

Products and services

  • eRapa Proprietary oral tablet formulation of rapamycin (sirolimus), an mTOR inhibitor, designed to improve bioavailability and achieve more consistent pharmacokinetics than existing formulations. Lead indication is familial adenomatous polyposis (FAP), a rare condition where the only successful treatment is bowel resection and patients otherwise progress to colorectal cancer. Rapamycin is already approved in the US for organ rejection in renal transplantation.
  • MTX240 (OPB-171775) Next-generation molecular glue (OPB-171775) targeting TKI-resistant gastrointestinal stromal tumor (GIST), a rare sarcoma with approximately 4,000-6,000 new US cases annually. Induces selective protein degradation to overcome standard-of-care limitations such as imatinib resistance. Licensed exclusively from Otsuka in all territories outside Japan.
  • Tolimidone Orally delivered, potent and selective inhibitor of lyn kinase, a member of the Src family of protein tyrosine kinases mainly expressed in hematopoietic cells, neural tissues, liver, and adipose tissue. Demonstrates glycemic control via insulin sensitization in animal models of diabetes and has potential to become a first-in-class blood glucose modulating agent for type 1 diabetes.
  • Serenta Trial Phase 3 clinical study evaluating eRapa versus placebo for the ability to improve clinical outcomes in patients with familial adenomatous polyposis (FAP). The study is open for enrollment in the US and is conducted through clinical trial sites.

Quantifiable outcome

  • eRapa is being readied for phase 3 registration study in familial adenomatous polyposis (FAP)
  • +2 more outcomes

Companies that use Midatech Pharma PLC

Customer profile

Segments3 records

Ideal customer profiles2 records

Midatech Pharma PLC technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Midatech Pharma PLC partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights5 records

Midatech Pharma PLC competitors and assessment

Company assessment

Direct peers

  • vTv Therapeutics: Clinical-stage biopharma with a Type 1 diabetes program, directly comparable to Biodexa's Tolimidone. Both pursue novel, non-insulin mechanisms for T1D glycemic control from a small-cap clinical base.
  • Deciphera Pharmaceuticals: Pioneered approved GIST therapy (Qinlock/ripretinib) for TKI-resistant disease. Operates in the same rare oncology niche as Biodexa's MTX240 and shares the same clinical-stage-to-commercial rare disease playbook.
  • Crinetics Pharmaceuticals: Clinical-stage biopharma developing treatments for endocrine and metabolic rare diseases. Comparable specialty-pharma positioning, therapeutic area overlap (endocrine/metabolic), and similar small-cap clinical-stage operating model.
  • Cogent Biosciences: Clinical-stage biopharma developing treatments for TKI-resistant GIST, directly overlapping with Biodexa's MTX240 program. Same rare sarcoma indication and similar resistance-focused mechanism positioning make it the closest direct comparable.
  • Provention Bio: Was focused on Type 1 diabetes therapies (teplizumab) before acquisition by Sanofi. Closely comparable to Biodexa in targeting T1D as a clinical-stage specialty biopharma.

Broad incumbents

  • Revolution Medicines: Larger clinical-to-commercial oncology company developing targeted therapies including protein degraders and RAS inhibitors. Operates in the same novel-mechanism oncology space as Biodexa but at a more advanced and broader scale.
  • Blueprint Medicines: Established precision oncology biopharma with approved kinase inhibitors and broader pipeline. Comparable in therapeutic area (targeted oncology) but at a more advanced commercial and scale stage than Biodexa.

Emerging players

  • Aprea Therapeutics: Clinical-stage company developing molecular glue / targeted protein degradation therapies in oncology. Mechanism overlap with Biodexa's MTX240 makes it a comparable emerging player in the same modality class.
  • Molecular Partners: Clinical-stage biopharma developing novel biologics including targeted protein degradation approaches. Comparable as a small-cap clinical-stage innovator pursuing novel therapeutic modalities in oncology and serious diseases.
  • Lexicon Pharmaceuticals: Small-cap biopharma with diabetes and metabolism programs historically. Shares Biodexa's small-cap, clinical-stage profile and metabolic disease focus, though its development stage differs.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Midatech Pharma PLC social profiles

Digital presence

Midatech Pharma PLC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Midatech Pharma PLC leadership team

Management profile

Number of profiles

Midatech Pharma PLC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Midatech Pharma PLC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Midatech Pharma PLC

What does Midatech Pharma PLC do?

Biodexa Pharmaceuticals PLC (formerly Midatech Pharma PLC) is a clinical-stage biopharmaceutical company developing a pipeline of therapeutics for rare and serious diseases with high unmet medical need. Its lead asset eRapa is a proprietary oral tablet formulation of rapamycin using nanotechnology and pH-sensitive polymers, being readied for a Phase 3 study in familial adenomatous polyposis (FAP). The pipeline also includes MTX240, a next-generation molecular glue licensed from Otsuka for TKI-resistant GIST, and Tolimidone, an oral lyn kinase inhibitor with potential first-in-class application in type 1 diabetes.

Is Midatech Pharma PLC a public or private company?

Midatech Pharma PLC is a public company. It is classified as public and is currently operating.

When was Midatech Pharma PLC founded?

Midatech Pharma PLC was founded in -1.

Who are Midatech Pharma PLC's main competitors?

Direct peers on record are vTv Therapeutics, Deciphera Pharmaceuticals, Crinetics Pharmaceuticals, Cogent Biosciences and Provention Bio. Broad incumbents are Revolution Medicines and Blueprint Medicines. Emerging players are Aprea Therapeutics, Molecular Partners and Lexicon Pharmaceuticals.

Does Midatech Pharma PLC have an API?

No public API is recorded for Midatech Pharma PLC.

What industry is Midatech Pharma PLC in?

Midatech Pharma PLC's product category is Clinical-Stage Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AdvfnBiodexa Reaches 100-Patient Enrollment Milestone in Phase 3 Serenta Trial as Key Analysis Timeline AcceleratesBiodexa Pharmaceuticals enrolled 100 patients in its Phase 3 Serenta trial of eRapa for Familial Adenomatous Polyposis, with recruitment at 29 US and European sites. The interim futility analysis and database lock could occur earlier than planned, potentially in early 2027, depending on event accrual. No filing timetable has been announced.Markets DailyBiodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Shares Shorted: Short Interest Down 93.2% in SeptemberShort interest in Biodexa Pharmaceuticals ADR fell 93.2% to 18,380 shares as of September 30th. The stock traded down 12.1% to $0.46, and a 1-8 reverse split is scheduled for October 26th. Weiss Ratings downgraded the stock to a sell rating.YahooBiodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross ProceedsBiodexa Pharmaceuticals entered a warrant exercise agreement with an accredited investor to purchase 2,204,218 ADSs at $1.05 each, generating approximately $2.3 million in gross proceeds. The investor will receive new unregistered warrants to buy up to 4,408,436 ADSs, exercisable for five years. Closing is expected on September 15, 2026.GlobeNewswireBiodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross ProceedsBiodexa Pharmaceuticals entered a warrant exercise agreement with an accredited investor to purchase 2,204,218 ADSs at $1.05 each, generating approximately $2.3 million in gross proceeds. The investor will receive new unregistered warrants to buy up to 4,408,436 ADSs, immediately exercisable for five years. Closing is expected on September 15, 2026.BiodexapharmaBiodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross ProceedsBiodexa Pharmaceuticals entered into a warrant exercise agreement with an accredited investor to exercise 2,204,218 ADSs at $1.05 each, generating approximately $2.3 million in gross proceeds. The investor will receive new unregistered warrants to purchase up to 4,408,436 ADSs, immediately exercisable for five years. Closing is expected on September 15, 2026.TipranksBiodexa Pharmaceuticals Secures $2.3 Million Via Warrant Exercise DealBiodexa Pharmaceuticals entered a warrant inducement agreement with an accredited investor on September 14–15, 2026, to exercise warrants for 2,204,218 ADSs at $1.05 each, generating about $2.3 million in cash. The company will issue new Series P warrants covering up to 4,408,436 ADSs, which are immediately exercisable with a five-year term.BioSpaceInterim results for the six months ended June 30, 2026Biodexa Pharmaceuticals reported interim results for the six months ended June 30, 2026, with R&D costs rising to £2.92 million and net cash used in operating activities of £4.61 million. The company raised $3.5 million in financing on July 1, 2026, and its cash balance at period end was £3.23 million.Ticker ReportBiodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest UpdateShort interest in Biodexa Pharmaceuticals ADR surged 593.2% to 33,356 shares as of August 31st, with 3.3% of shares short sold. Armistice Capital acquired a new 100,000-share stake, and Weiss Ratings raised the stock to a sell (e+) rating. The stock traded up $0.64 to $1.30 on Friday.Quiver QuantitativeBiodexa Pharmaceuticals Reports Interim 2026 Results, Progress in eRapa and MTX240 Programs, and $3.5 Million Post-Period Fundraise | BDRX Stock NewsBiodexa Pharmaceuticals reported interim results for the six months ended June 30, 2026, with R&D costs rising 75% to £2.92 million and a net cash outflow of £5.31 million. The company raised $3.5 million on July 1, 2026, and its cash balance stood at £3.23 million. It also in-licensed MTX240 and expanded its eRapa trial into Canada.GlobeNewswireBiodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and WarrantsBiodexa Pharmaceuticals priced a $3.5 million registered direct offering and concurrent private placement of pre-funded warrants and warrants. The offering includes 282,952 ADSs at $2.85 each and warrants to purchase up to 2,194,218 ADSs, with proceeds expected to fund development programs and working capital.